American Diabetes Association
DC_appendix_revised_version3_clean.pdf (5.71 MB)

A Rare Variant in Metallothionein 1E Increases the Risk for Type 2 Diabetes in a Chinese Population

Download (5.71 MB)
posted on 2023-10-25, 00:10 authored by Xiantong Zou, Mengdie Hu, Xiuting Huang, Lingli Zhou, Meng Li, JING CHEN, Liping Ma, Xueying Gao, Yingying Luo, Xiaoling Cai, Yufeng Li, Xianghai Zhou, Na Li, Yuanping Shi, Xueyao Han, Linong Ji

Objective: To uncover novel targets for the treatment of type 2 diabetes (T2D) by investigating rare variants with large effects in monogenic forms of the disease.

Research Design and Methods: We performed whole-exome sequencing in a family with diabetes. We validated the identified gene using Sanger sequencing in additional families, diabetes and community-based cohorts. Wild-type and variant gene transgenic mouse models were used to study the gene function.

Results: Our analysis revealed a rare variant of the metallothionein 1E (MT1E) gene, p.C36Y, in a three-generation family with diabetes. This risk allele was associated with T2D or pre-diabetes in a community-based cohort. MT1E p.C36 carriers had higher HbA1c levels and BMI than those carrying the wild-type allele. Mice with forced expression of MT1E p.C36Y demonstrated increased weight gain, elevated post-challenge serum glucose levels and liver enzyme levels, and hepatic steatosis, similar to the phenotypes observed in human carriers of MT1E p.C36Y. In contrast, mice with forced expression of MT1E p.C36C displayed reduced weight and serum glucose and serum triglyceride levels. Forced expression of the wild-type and variant MT1E demonstrated differential expression of genes related to lipid metabolism.

Conclusion: Our results suggest that MT1E could be a promising target for drug development, as MT1E p.C36C forced expression stabilizes glucose metabolism and reduces body weight, whereas MT1E p.C36Y has the opposite effect. These findings highlight the importance of considering the impact of rare variants in the development of new T2D treatments.


This work was supported by the Research Key Project of the Ministry of Science and Technology of the People’s Republic of China (2016YFC1304901), the National High-technology Research and Development Program of China (2012AA02A509) and the Beijing Nature Science (7142163).


Usage metrics

    Diabetes Care


    Ref. manager